Keywords: aeterna, reports, strong, data, growth, disorder, drug

AEterna reports strong data for growth disorder drug

Article | 25 April 2005

Print This

Canadian oncology and endocrine-focused firm AEterna Zentaris has posted positive results from a Phase I study of its oral growth ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in